The Experts below are selected from a list of 57 Experts worldwide ranked by ideXlab platform
Raymond Alexanian - One of the best experts on this subject based on the ideXlab platform.
-
solitary bone plasmacytoma outcome and prognostic factors following radiotherapy
International Journal of Radiation Oncology Biology Physics, 1998Co-Authors: Robert H Liebross, Kay Delasalle, Chul S Ha, Donna M Weber, Raymond AlexanianAbstract:Abstract Purpose: To clarify the natural history of solitary plasmacytoma of bone (SBP) after radiation treatment. Methods and Materials: Between 1965–1996, we identified 57 previously untreated patients with a SBP. A serum Myeloma Protein was present in 33 patients (58%) and Bence Jones Proteinuria was present in an additional eight patients (14%). The median radiotherapy dose was 50 Gy (range, 30–70 Gy). Overall survival, cause-specific survival, and freedom from progression to multiple Myeloma were calculated actuarially. Results: Local control was achieved in 55 of 57 patients (96%). For those 29 patients (51%) who subsequently developed multiple Myeloma, the median time to progression was 1.8 years. There was a direct correlation between persistence of abnormal Protein following radiotherapy and the likelihood of developing multiple Myeloma. Among 11 patients with disappearance of Myeloma Protein, only two developed multiple Myeloma after 4 and 12 years, in contrast to progression in 57% of patients with a persistent Protein peak and 63% of those with nonsecretory disease ( p = 0.02). Among 23 patients with thoracolumbar spine disease, 7 of 8 patients staged with plain radiographs alone developed multiple Myeloma in comparison with 1 of 7 patients who also had magnetic resonance imaging (MRI) ( p = 0.08). For all patients, the median survival from radiotherapy was 11.0 years. The median cause-specific survival of patients with disappearance of Myeloma Protein was significantly longer than that of the remaining patients ( p = 0.004). Conclusion: Results supported the importance of precise staging that includes MRI of the spine for optimum patient selection and the application of definitive radiotherapy. Those patients with Myeloma Protein that disappears following radiotherapy represent a category with a high likelihood of cure.
-
curability of solitary bone plasmacytoma
Journal of Clinical Oncology, 1992Co-Authors: Meletios A Dimopoulos, J Goldstein, Lillian M Fuller, Kay Delasalle, Raymond AlexanianAbstract:PURPOSEThe effects of involved-field radiotherapy were assessed in patients with a solitary plasmacytoma of bone (SBP).PATIENTS AND METHODSForty-five consecutive patients with an SBP received megavoltage irradiation of at least 3,000 cGy. The median age was 53 years, 67% of patients showed a Myeloma Protein, and uninvolved immunoglobulins (Igs) were preserved in 93% of patients.RESULTSPermanent control of presenting disease was achieved in all but two patients, but 46% of patients developed multiple Myeloma. When it occurred, progression of Myeloma occurred within 3 years in two thirds of the patients, suggesting that the extent of disease was understaged at diagnosis. Myeloma Protein disappeared in nine patients (30%) whose disease has not yet recurred. The median survival for all patients was 13 years and the Myeloma-specific survival fraction at 10 years was 53%.CONCLUSIONIn patients with an SBP, the disappearance of Myeloma Protein with involved-field radiotherapy predicted long-term disease-free surv...
-
Curability of solitary bone plasmacytoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992Co-Authors: Meletios A Dimopoulos, J Goldstein, Lillian M Fuller, Kay Delasalle, Raymond AlexanianAbstract:PURPOSEThe effects of involved-field radiotherapy were assessed in patients with a solitary plasmacytoma of bone (SBP).PATIENTS AND METHODSForty-five consecutive patients with an SBP received megavoltage irradiation of at least 3,000 cGy. The median age was 53 years, 67% of patients showed a Myeloma Protein, and uninvolved immunoglobulins (Igs) were preserved in 93% of patients.RESULTSPermanent control of presenting disease was achieved in all but two patients, but 46% of patients developed multiple Myeloma. When it occurred, progression of Myeloma occurred within 3 years in two thirds of the patients, suggesting that the extent of disease was understaged at diagnosis. Myeloma Protein disappeared in nine patients (30%) whose disease has not yet recurred. The median survival for all patients was 13 years and the Myeloma-specific survival fraction at 10 years was 53%.CONCLUSIONIn patients with an SBP, the disappearance of Myeloma Protein with involved-field radiotherapy predicted long-term disease-free surv...
Kay Delasalle - One of the best experts on this subject based on the ideXlab platform.
-
solitary bone plasmacytoma outcome and prognostic factors following radiotherapy
International Journal of Radiation Oncology Biology Physics, 1998Co-Authors: Robert H Liebross, Kay Delasalle, Chul S Ha, Donna M Weber, Raymond AlexanianAbstract:Abstract Purpose: To clarify the natural history of solitary plasmacytoma of bone (SBP) after radiation treatment. Methods and Materials: Between 1965–1996, we identified 57 previously untreated patients with a SBP. A serum Myeloma Protein was present in 33 patients (58%) and Bence Jones Proteinuria was present in an additional eight patients (14%). The median radiotherapy dose was 50 Gy (range, 30–70 Gy). Overall survival, cause-specific survival, and freedom from progression to multiple Myeloma were calculated actuarially. Results: Local control was achieved in 55 of 57 patients (96%). For those 29 patients (51%) who subsequently developed multiple Myeloma, the median time to progression was 1.8 years. There was a direct correlation between persistence of abnormal Protein following radiotherapy and the likelihood of developing multiple Myeloma. Among 11 patients with disappearance of Myeloma Protein, only two developed multiple Myeloma after 4 and 12 years, in contrast to progression in 57% of patients with a persistent Protein peak and 63% of those with nonsecretory disease ( p = 0.02). Among 23 patients with thoracolumbar spine disease, 7 of 8 patients staged with plain radiographs alone developed multiple Myeloma in comparison with 1 of 7 patients who also had magnetic resonance imaging (MRI) ( p = 0.08). For all patients, the median survival from radiotherapy was 11.0 years. The median cause-specific survival of patients with disappearance of Myeloma Protein was significantly longer than that of the remaining patients ( p = 0.004). Conclusion: Results supported the importance of precise staging that includes MRI of the spine for optimum patient selection and the application of definitive radiotherapy. Those patients with Myeloma Protein that disappears following radiotherapy represent a category with a high likelihood of cure.
-
curability of solitary bone plasmacytoma
Journal of Clinical Oncology, 1992Co-Authors: Meletios A Dimopoulos, J Goldstein, Lillian M Fuller, Kay Delasalle, Raymond AlexanianAbstract:PURPOSEThe effects of involved-field radiotherapy were assessed in patients with a solitary plasmacytoma of bone (SBP).PATIENTS AND METHODSForty-five consecutive patients with an SBP received megavoltage irradiation of at least 3,000 cGy. The median age was 53 years, 67% of patients showed a Myeloma Protein, and uninvolved immunoglobulins (Igs) were preserved in 93% of patients.RESULTSPermanent control of presenting disease was achieved in all but two patients, but 46% of patients developed multiple Myeloma. When it occurred, progression of Myeloma occurred within 3 years in two thirds of the patients, suggesting that the extent of disease was understaged at diagnosis. Myeloma Protein disappeared in nine patients (30%) whose disease has not yet recurred. The median survival for all patients was 13 years and the Myeloma-specific survival fraction at 10 years was 53%.CONCLUSIONIn patients with an SBP, the disappearance of Myeloma Protein with involved-field radiotherapy predicted long-term disease-free surv...
-
Curability of solitary bone plasmacytoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992Co-Authors: Meletios A Dimopoulos, J Goldstein, Lillian M Fuller, Kay Delasalle, Raymond AlexanianAbstract:PURPOSEThe effects of involved-field radiotherapy were assessed in patients with a solitary plasmacytoma of bone (SBP).PATIENTS AND METHODSForty-five consecutive patients with an SBP received megavoltage irradiation of at least 3,000 cGy. The median age was 53 years, 67% of patients showed a Myeloma Protein, and uninvolved immunoglobulins (Igs) were preserved in 93% of patients.RESULTSPermanent control of presenting disease was achieved in all but two patients, but 46% of patients developed multiple Myeloma. When it occurred, progression of Myeloma occurred within 3 years in two thirds of the patients, suggesting that the extent of disease was understaged at diagnosis. Myeloma Protein disappeared in nine patients (30%) whose disease has not yet recurred. The median survival for all patients was 13 years and the Myeloma-specific survival fraction at 10 years was 53%.CONCLUSIONIn patients with an SBP, the disappearance of Myeloma Protein with involved-field radiotherapy predicted long-term disease-free surv...
Meletios A Dimopoulos - One of the best experts on this subject based on the ideXlab platform.
-
curability of solitary bone plasmacytoma
Journal of Clinical Oncology, 1992Co-Authors: Meletios A Dimopoulos, J Goldstein, Lillian M Fuller, Kay Delasalle, Raymond AlexanianAbstract:PURPOSEThe effects of involved-field radiotherapy were assessed in patients with a solitary plasmacytoma of bone (SBP).PATIENTS AND METHODSForty-five consecutive patients with an SBP received megavoltage irradiation of at least 3,000 cGy. The median age was 53 years, 67% of patients showed a Myeloma Protein, and uninvolved immunoglobulins (Igs) were preserved in 93% of patients.RESULTSPermanent control of presenting disease was achieved in all but two patients, but 46% of patients developed multiple Myeloma. When it occurred, progression of Myeloma occurred within 3 years in two thirds of the patients, suggesting that the extent of disease was understaged at diagnosis. Myeloma Protein disappeared in nine patients (30%) whose disease has not yet recurred. The median survival for all patients was 13 years and the Myeloma-specific survival fraction at 10 years was 53%.CONCLUSIONIn patients with an SBP, the disappearance of Myeloma Protein with involved-field radiotherapy predicted long-term disease-free surv...
-
Curability of solitary bone plasmacytoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992Co-Authors: Meletios A Dimopoulos, J Goldstein, Lillian M Fuller, Kay Delasalle, Raymond AlexanianAbstract:PURPOSEThe effects of involved-field radiotherapy were assessed in patients with a solitary plasmacytoma of bone (SBP).PATIENTS AND METHODSForty-five consecutive patients with an SBP received megavoltage irradiation of at least 3,000 cGy. The median age was 53 years, 67% of patients showed a Myeloma Protein, and uninvolved immunoglobulins (Igs) were preserved in 93% of patients.RESULTSPermanent control of presenting disease was achieved in all but two patients, but 46% of patients developed multiple Myeloma. When it occurred, progression of Myeloma occurred within 3 years in two thirds of the patients, suggesting that the extent of disease was understaged at diagnosis. Myeloma Protein disappeared in nine patients (30%) whose disease has not yet recurred. The median survival for all patients was 13 years and the Myeloma-specific survival fraction at 10 years was 53%.CONCLUSIONIn patients with an SBP, the disappearance of Myeloma Protein with involved-field radiotherapy predicted long-term disease-free surv...
Mel Greaves - One of the best experts on this subject based on the ideXlab platform.
-
rapid positive selection of cd34 cells using magnetic microspheres coated with monoclonal antibody qbend 10 linked via a cleavable disulphide bond
Leukemia, 1993Co-Authors: P G Grimsley, T A S Amos, M Y Gordon, Mel GreavesAbstract:Positive selection of CD34+ cells has applications in diagnostic pathology, in peripheral blood and bone marrow transplantation, and in studies on the function and regulation of primitive haemopoietic stem cells. Antibody-coated magnetic microspheres (dynabeads) can be used to isolate these cells by positive selection procedures. However, the advantages of using dynabeads in some positive selection protocols are compromised by the retention of the beads on the cells. We present a protocol which allows the rapid chemical release of the beads from positively sorted cells. The murine immunoglobulin (Ig) G1 CD34 antibody, QBEND/10, was immobilised onto dynabeads as part of a three-layered immune complex: QBEND/10 was attached to F(ab')2 anti-mouse immunoglobulin antibody fragments, which were immunologically bound to a mouse IgG1 Myeloma Protein. The Myeloma Protein covalently bonded the triplex to the beads. Thus, disulphide bonds in the hinge region of the F(ab')2 could be reduced with 10 microM dithiothreitol and CD34+ cells released within 20 min. Purified cells can be re-phenotyped by multiple markers and subsets identified. Purity of 97%, recovery of > 50%, and viability over 90% of the CD34+ cells was readily achieved. Furthermore, granulocyte-macrophage colony-forming cells were retained in the positive fraction. This methodology can be used to purify other cell types, including T and B lymphocytes.
J Goldstein - One of the best experts on this subject based on the ideXlab platform.
-
curability of solitary bone plasmacytoma
Journal of Clinical Oncology, 1992Co-Authors: Meletios A Dimopoulos, J Goldstein, Lillian M Fuller, Kay Delasalle, Raymond AlexanianAbstract:PURPOSEThe effects of involved-field radiotherapy were assessed in patients with a solitary plasmacytoma of bone (SBP).PATIENTS AND METHODSForty-five consecutive patients with an SBP received megavoltage irradiation of at least 3,000 cGy. The median age was 53 years, 67% of patients showed a Myeloma Protein, and uninvolved immunoglobulins (Igs) were preserved in 93% of patients.RESULTSPermanent control of presenting disease was achieved in all but two patients, but 46% of patients developed multiple Myeloma. When it occurred, progression of Myeloma occurred within 3 years in two thirds of the patients, suggesting that the extent of disease was understaged at diagnosis. Myeloma Protein disappeared in nine patients (30%) whose disease has not yet recurred. The median survival for all patients was 13 years and the Myeloma-specific survival fraction at 10 years was 53%.CONCLUSIONIn patients with an SBP, the disappearance of Myeloma Protein with involved-field radiotherapy predicted long-term disease-free surv...
-
Curability of solitary bone plasmacytoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992Co-Authors: Meletios A Dimopoulos, J Goldstein, Lillian M Fuller, Kay Delasalle, Raymond AlexanianAbstract:PURPOSEThe effects of involved-field radiotherapy were assessed in patients with a solitary plasmacytoma of bone (SBP).PATIENTS AND METHODSForty-five consecutive patients with an SBP received megavoltage irradiation of at least 3,000 cGy. The median age was 53 years, 67% of patients showed a Myeloma Protein, and uninvolved immunoglobulins (Igs) were preserved in 93% of patients.RESULTSPermanent control of presenting disease was achieved in all but two patients, but 46% of patients developed multiple Myeloma. When it occurred, progression of Myeloma occurred within 3 years in two thirds of the patients, suggesting that the extent of disease was understaged at diagnosis. Myeloma Protein disappeared in nine patients (30%) whose disease has not yet recurred. The median survival for all patients was 13 years and the Myeloma-specific survival fraction at 10 years was 53%.CONCLUSIONIn patients with an SBP, the disappearance of Myeloma Protein with involved-field radiotherapy predicted long-term disease-free surv...
